Search

A new report from the Maria Sklodowska-Curie National Research Institute of Oncology presents fresh data on breast cancer. The study focuses on hepatic visceral crisis (VC), a life-threatening risk in advanced breast cancer, and explores the safety and efficacy of cisplatin monotherapy as a treatment option for patients with HER-2 negative breast cancer experiencing hepatic VC/IVC. The study found that cisplatin may be a viable option for these patients, regardless of liver function parameters and other factors. The research highlights the need for specific recommendations for systemic treatment due to the hepatotoxicity of breast cancer drugs. [Extracted from the article]

The article discusses the research from Lausanne University Hospital, which reveals that second-line folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy for advanced biliary cancers, after initial treatment with cisplatin/gemcitabine, shows moderate efficacy. The meta-analysis indicates an overall response rate of 10.42 percent, with a median progression-free survival of 3.03 months, highlighting FOLFOX's potential as a benchmark for evaluating new treatments.

The article focuses on a clinical trial investigating the effectiveness of drug gemcitabine/cisplatin plus cemiplimab, with or without fianlimab, in treating bladder cancer. It explains that participants are randomly assigned to receive either the full regimen or a combination without fianlimab, followed by a series of treatments and evaluations, including repeat tumor resections and imaging.

A report from Shanxi Medical University in China discusses the potential for a drug called ABT-737 to increase the sensitivity of ovarian cancer cells to cisplatin, a common chemotherapy drug. The study found that ABT-737 can activate a signaling pathway involving reactive oxygen species (ROS), ASK1, and JNK, which plays a role in increasing cisplatin sensitivity in resistant ovarian cancer cells. The research suggests that targeting this pathway could be a novel therapeutic strategy for patients with cisplatin-resistant ovarian cancer. The study was supported by the National Natural Science Foundation of China. [Extracted from the article]

Researchers at Jilin Agricultural University in Changchun, China have found that tangeretin, a natural compound found in citrus peel, may protect against heart damage caused by cisplatin, a common chemotherapy drug. The study showed that tangeretin effectively countered cisplatin-induced damage in heart cells and improved cardiac function in animal models. The researchers believe that tangeretin activates AMPK, reduces the inactivation of Acetyl-CoA Carboxylase (ACC) protein, inhibits p38 MAPK, and prevents mitochondrial dysfunction and cell death. This research suggests that tangeretin has potential in safeguarding the heart from cisplatin-induced harm. [Extracted from the article]

The article focuses on the early termination of the PROOF 301 trial comparing the oral FGFR inhibitor infigratinib to gemcitabine plus cisplatin in treating cholangiocarcinoma. Topics include the preliminary efficacy and safety data of infigratinib, the challenges faced in biomarker-selected studies, and the implications for future confirmatory research in rare tumors.

The article reports on a study from the Dorn Research Institute that investigates whether fluoxetine and fluvoxamine can reduce cisplatin-induced hearing loss or tinnitus in veterans. Topics discussed include the potential protective effect of these antidepressants against ototoxicity, the use of a retrospective cohort study design, and the need for further randomized clinical trials to confirm these findings.

A recent study conducted in Weifang, China, has revealed promising findings in the treatment of adrenocortical carcinoma (ACC), a rare and aggressive tumor that affects the adrenal cortex. The study focused on a 66-year-old man with metastatic ACC who underwent treatment with a combination of etoposide, cisplatin, sintilimab, and anlotinib. The patient experienced a significant reduction in lung metastases and the disappearance of the adrenal mass, with no disease progression observed. The study suggests that this novel combination therapy could be a safe and effective option for patients with ACC. [Extracted from the article]

A clinical trial, NCT06557889, is currently recruiting participants in France to evaluate a treatment for recurrent or metastatic head and neck squamous cell carcinoma. The trial aims to compare the effectiveness of 4 cycles of chemotherapy in combination with pembrolizumab to the standard 6 cycles of chemotherapy. The primary outcome measures include objective response rate and safety, while secondary outcome measures include objective response rate at 6 months, progression-free survival, overall survival, and duration of response. Eligibility criteria for the trial include being at least 18 years old, having a confirmed diagnosis of the cancer, not having received previous systemic therapy for the disease, and having a documented Combined Positive Score (CPS) PD-L1 of at least 1. Exclusion criteria include certain diseases or conditions, pregnancy or breastfeeding, and previous treatment with certain medications. [Extracted from the article]

The article from Chung Shan Medical University reports new insights into colon cancer treatment. Topics include the potentiation of cisplatin's cytotoxicity against colorectal cancer cells by rosmarinic acid (RA), the enhancement of apoptosis and ferroptosis mechanisms by RA, and the signaling pathway changes observed in colon cancer cell lines treated with RA and cisplatin.

A patent application titled "Combination Of Bi853520 With Chemotherapeutic Drugs" has been published online. The inventors propose the use of BI853520, a specific compound, in combination with chemotherapeutic drugs for the treatment of various types of tumors, including breast cancer, lung cancer, colon cancer, ovarian cancer, and more. The inventors aim to improve the efficacy of chemotherapy and overcome drug resistance, which is a major challenge in cancer treatment. The patent application provides detailed information on the structure of BI853520 and its potential use in combination with different chemotherapeutic drugs. [Extracted from the article]

A study conducted at Khon Kaen University in Thailand explored the potential of Valencia peanut skin extract (KK4-PSE) in inhibiting the growth of cervical cancer cells. The study found that KK4-PSE, when combined with cisplatin or 5-fluorouracil (5-FU), demonstrated antiproliferative activity against HeLa cells in vitro and in xenograft models. The combination of KK4-PSE and 5-FU showed a synergistic effect, reducing tumor weights and mitigating hepatotoxicity in nude mouse xenograft models. These findings suggest that KK4-PSE has the potential to limit cervical cancer cell proliferation while reducing the toxicity of cisplatin and 5-FU. [Extracted from the article]

The article from Tehran University of Medical Sciences explores how short-term fasting can influence the efficacy of cisplatin in treating oral squamous cell carcinoma (HNSCC). Topics discussed include the impact of fasting on cell viability in HN5 cancer cells, differences in effects on healthy keratinocyte cells, and the increased apoptosis and necrosis observed with fasting combined with chemotherapy.

The article explores new findings on liver cancer treatment involving Ocimum gratissimum (OGE) and its potential to enhance chemotherapy. Topics discussed include OGE's impact on hepatocellular carcinoma cells, its synergistic effect with cisplatin, and the underlying mechanism involving BRCA1 inhibition.

A recent report from the University of Ngaoundere discusses the production of dextrin from sweet potato starch through a process called pyroconversion. The study examines the effects of roasting time, temperature, and hydrochloric acid concentration on the structural and functional properties of the starch. The research found that temperature and hydrochloric acid concentration were the most influential factors in the pyroconversion process. The optimal conditions for dextrin production were determined to be 94 minutes of roasting time, 127°C temperature, and 0.43 M hydrochloric acid concentration. The study concludes that these pyrodextrins could be used as encapsulating agents or additives in the food and chemical industries. [Extracted from the article]

The article discusses a new clinical trial, which is investigating the impact of statins on reducing ototoxicity caused by platinum-based chemotherapy, specifically cisplatin. Topics include the high incidence of ototoxicity in chemotherapy patients, the potential protective effects of statins, and the need for further research to confirm these findings in human trials.

The article reports on a research from the University of Alabama at Birmingham investigating the impact of cisplatin therapy on histone deacetylase (HDAC) expression in male and female mice with acute kidney injury. Topics include sex differences in HDAC expression, kidney injury mechanisms, and cisplatin's effects on HDAC localization and activity.

The article focuses on a new clinical trial (NCT06548412) investigating the addition of CTX-009 to the standard therapy for patients with unresectable or metastatic biliary tract cancers. Topics include the trial's objectives to evaluate safety and efficacy, the combination of CTX-009 with gemcitabine, cisplatin, and durvalumab, and the study's design and recruitment status.

The article focuses on a multicenter, single-arm phase II trial evaluating Tislelizumab combined with chemotherapy and concurrent thoracic radiotherapy for treating extensive-stage small-cell lung cancer (ES-SCLC). Topics include the preliminary efficacy and safety of this combination therapy, the trial's design and methodology, and its role as a first-line treatment for ES-SCLC.

The article focuses on the treatment of postoperative loco-regional recurrent esophageal cancer, topics include a phase II study of radiotherapy combined with docetaxel, cisplatin, and 5-fluorouracil, and the efficacy and safety of chemoradiotherapy. It study aimed to evaluate the effectiveness of radiotherapy combined with chemotherapy in patients with recurrent esophageal cancer after surgery.

The article focuses on a single-arm, Phase II clinical study designed to evaluate the efficacy and safety of a combination treatment involving sintilimab, bevacizumab, pemetrexed, and cisplatin for patients with unresectable malignant peritoneal mesothelioma. It aims to measure Progression-Free Survival (PFS) as the primary outcome, while secondary outcomes include Overall Survival (OS), Objective Response Rate (ORR), and Disease Control Rate (DCR).

The article focuses on the role of ISG15 in accelerating acute kidney injury (AKI) and the transition from AKI to chronic kidney disease (CKD). Topics include the upregulation of ISG15 in various AKI models, its promotion of TGF-βR1 ISGylation and impact on fibrosis, and the effects of ISG15 knockout on kidney injury and fibrosis.

A new study conducted by researchers at the Department of Oncology explores the potential of icariin, a natural antioxidant derived from Epimedium brevicornum Maxim., in protecting against premature ovarian failure (POF) induced by cisplatin, a commonly used chemotherapeutic drug. The study found that icariin treatment increased body weight, ovarian weight, and the number of follicles, and improved the oestrous cycle in POF mice. Icariin also reduced oxidative damage, inhibited apoptosis, and activated the Nrf2 pathway, which may contribute to its protective effects against POF. These findings provide new insights into the potential mechanisms by which icariin prevents POF. [Extracted from the article]

A recent report from the Department of Obstetrics and Gynecology highlights the potential for KDM1A inhibitors to enhance the response to chemotherapy in ovarian cancer. The study found that KDM1A, an epigenetic modifier, is overexpressed in ovarian cancer and is associated with poor response to chemotherapy. Inhibition of KDM1A using specific inhibitors sensitized ovarian cancer cells to chemotherapy drugs, reducing cell viability and inducing apoptosis. Additionally, the combination of KDM1A inhibition and chemotherapy reduced tumor growth in a mouse model. These findings suggest that combining KDM1A inhibitors with chemotherapy could be a promising therapeutic approach for ovarian cancer treatment. [Extracted from the article]

A new study conducted by researchers at Xi'an Jiaotong University in China explores the mechanisms underlying cisplatin resistance in high-grade serous ovarian cancer (HGSOC). The study used various datasets and molecular biology experiments to identify differentially expressed miRNAs and mRNAs and construct a network between miR-486-3p and TMIGD2. The experiments showed that low miR-486-3p or high TMIGD2 expression increased migratory rate and cisplatin resistance, while overexpression of miR-486-3p or downregulation of TMIGD2 decreased migration rate and enhanced sensitivity to cisplatin treatment. The findings provide insights for the development of novel therapeutic approaches. The study was published in the journal Heliyon. [Extracted from the article]

A recent study conducted in Montreal, Canada, has found that acute kidney injury (AKI) is a common side effect of cisplatin therapy. The study identified several factors that increase the risk of AKI, including age over 60, hypertension, high cisplatin dose, diabetes, and low serum albumin levels. Additionally, the study found that hypokalemia, hypomagnesemia, and hyponatremia are associated with an increased risk of AKI in patients treated with cisplatin. The researchers recommend further studies to explore the role of electrolyte disorders as predictive risk factors for AKI in this patient population. [Extracted from the article]

A new report discusses research on squamous cell carcinoma, specifically focusing on the clinical predictors of ototoxicity in patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) who undergo cisplatin chemoradiation. The study found that high-dose cisplatin administration, higher cochlear radiation doses, a history of smoking, and older age were all independently associated with an increased risk of ototoxicity. The researchers suggest that further studies are needed to develop risk stratification and interventions to reduce the risk of ototoxicity in this population. [Extracted from the article]

A recent study conducted by researchers at the School of Life Sciences and Technology in Shandong, China, has found that the encapsulation of the drug cisplatin within liposomes modified with peanut agglutinin (PNA) can improve its efficacy in treating non-small cell lung cancer (NSCLC). NSCLC is a major global health threat and accounts for over 80% of lung cancer cases. The study aimed to enhance the delivery of cisplatin to tumor tissues and reduce associated side effects. In vitro and in vivo experiments showed that PNA-modified liposomes resulted in higher uptake by cells and a significant enhancement of tumor suppression compared to free cisplatin. These findings provide valuable insights for the development of clinical drug therapies. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the development of a 3-in-1 nanotherapeutic approach for ovarian cancer. Ovarian cancer is a challenging disease to treat, and platin-based chemotherapy is the primary option but limited by drug resistance mechanisms. The researchers explored a combination approach using cisplatin, olaparib, and metformin encapsulated in nanoparticles. In vitro evaluation showed that each agent in the nanoparticles was active and contributed to killing ovarian cancer cells at lower concentrations. This research provides insight into developing novel nanotherapeutic strategies for improving ovarian cancer treatment. [Extracted from the article]

The Wistar Institute of Anatomy and Biology has been issued a patent for methods of treating cancers that overexpress arginine methyltransferase CARM1 with EZH2 inhibitors and a PARP inhibitor. Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy in the United States, and platinum-based therapies like cisplatin are the standard of care. However, many patients become resistant to cisplatin, and the mechanism of this resistance is not fully understood. The invention involves administering a therapeutically effective dose of an EZH2 inhibitor and a PARP inhibitor to treat cancer in patients with overexpressed CARM1. [Extracted from the article]

A recent study conducted by Southern Medical University in Guangzhou, China, explores the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to sensitize cisplatin (CDDP) in the treatment of ovarian cancer (OC). However, widely used NSAIDs such as celecoxib and naproxen carry an increased risk of cardiovascular events. To address this issue, the researchers developed a new approach using reactive oxygen species (ROS)-responsive composite nano-hydrangeas loaded with allicin and platinum(IV) prodrug. This approach achieved comprehensive chemosensitization by blocking COX-2 and employing multifaceted mechanisms to enhance OC treatment outcomes. [Extracted from the article]

A recent study conducted at University College Cork examined the effectiveness of the chemotherapy regimen paclitaxel, ifosfamide, and cisplatin (TIP) as a salvage treatment for germ cell tumors (GCT). The study included a large cohort of patients with both favorable and unfavorable risk factors. The results showed that TIP was effective in treating GCT, with similar outcomes observed in patients with both favorable and unfavorable risk factors. The study also mentioned an ongoing clinical trial that will compare TIP with high-dose chemotherapy to determine the optimal second-line treatment approach. [Extracted from the article]

A report from Nanchang University in the People's Republic of China discusses the function of USP14 in retinoblastoma (RB) and its sensitivity to cisplatin (DDP). The study found that by silencing USP14 in RB cells, levels of resistance-related proteins, ferroptosis-related proteins, and lipid metabolism-related proteins were reduced, accompanied by increased apoptosis and enhanced ROS levels. This suggests that USP14 may suppress DDP resistance in RB by mediating ferroptosis, making it an important target for treating RB. The research was supported by the Foundation of Jiangxi Provincial Health Department. [Extracted from the article]

This document provides information about a Phase IB/II clinical trial being conducted by Shanghai Hengrui Pharmaceutical Co., Ltd. The trial aims to evaluate the safety, tolerability, and efficacy of SHR-A2102 with Adebrelimab for the treatment of advanced or metastatic non-small cell lung cancer. The study is interventional and in Phase 1/Phase 2, with a primary purpose of treatment. The trial will assess various outcome measures, including response rate, disease control rate, duration of response, progression-free survival, and overall survival. The study is investigating the use of a combination of drugs, including SHR-A2102, Adebrelimab, and Cisplatin/Carboplatin, for the treatment of non-small cell lung squamous cell carcinoma. The study is not yet recruiting participants, and the expected completion date is October 2026. The eligibility criteria for participants are outlined, and the study is open to individuals of all genders between the ages of 18 and 70. The study is taking place in China. [Extracted from the article]

A new report discusses research findings on biomarkers related to the use of cisplatin, an anticancer drug, and its effects on hepatotoxicity in rats. The study aimed to evaluate the hepatotoxicity caused by cisplatin and the potential amelioration of this toxicity through the co-administration of either curcumin or resveratrol. The research involved administering cisplatin to rats and then giving them either curcumin or resveratrol for a period of 28 days. The results showed that the co-administration of either curcumin or resveratrol with cisplatin reduced hepatotoxicity by improving liver enzymes, reducing oxidative stress markers, and improving microscopic structural changes in the liver tissues. The study suggests that the anti-inflammatory and oxidative stress-apoptotic pathways may be involved in this amelioration. [Extracted from the article]